Wednesday, June 8, 2011

Roche Molecular Diagnostics, Merck ink cancer assay deal

Roche Molecular Diagnostics will develop diagnostic assays for Merck & Co. that will help the drug giant developer cancer drugs.
Financial terms of the deal between Pleasanton-based Roche Molecular Diagnostics and Merck (NYSE: MRK) were not disclosed.

No comments:

Post a Comment